methoctramine and Carcinoma, Non-Small Cell Lung

methoctramine has been researched along with Carcinoma, Non-Small Cell Lung in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, H; Gu, X; Lu, Q; Xu, L; Zhang, C; Zhao, Q	1

Other Studies

1 other study(ies) available for methoctramine and Carcinoma, Non-Small Cell Lung

Article	Year
Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC). Cancer biology & therapy, 2015, Volume: 16, Issue:4 Topics: Acetylcholine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diamines; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Muscarinic M2; Signal Transduction	2015

Article

Year

Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).

Cancer biology & therapy, 2015, Volume: 16, Issue:4

Topics: Acetylcholine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diamines; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Muscarinic M2; Signal Transduction

2015